KEY FINDINGS
The global hormone replacement therapy market is estimated to project a CAGR of 7.67% during the forecast period, 2021-2028. The awareness of post-menopausal issues, product launches by major players, and growing hormonal disorders drive market growth.
MARKET INSIGHTS
HRT (hormone replacement therapy) replaces hormones like thyroid hormone, progestogen hormone, human growth hormone, and estrogen hormone. One of the significant drivers of market growth is the increasing product launches by major players.
Several players are launching new products to reinforce their foothold in the competitive market. Novo Nordisk received the FDA approval for Sogroya (somapacitan-beco) in 2020 for adult growth hormone deficiency. As a result, the company extended its product reach across the US. Mylan launched Estradiol Vaginal Cream USP in 2018 for treating vaginal and vulvar atrophy. This strengthened its women's healthcare portfolio in several hormone replacement therapy-related disorders. Abbott expanded its product portfolio through its launch of Thyronorm 37.5 mcg tablet for hypothyroidism and Estrabet gel in 2019. Such developments are propelling the market growth. However, the treatment costs and adverse reactions related to HRT hamper the market growth.
REGIONAL INSIGHTS
The global hormone replacement therapy market is geographically segmented into North America, Asia-Pacific, Europe, and Rest of World for growth assessment. With increasing awareness among end-users and improving healthcare infrastructure, Asia-Pacific is evaluated to record the highest CAGR.
COMPETITIVE INSIGHTS
The rising market expansion by players is projected to increase the competitive rivalry. Amgen, Bayer AG, Eli Lilly & Company, ANI Pharmaceuticals, Genentech Inc, Abbott Laboratories, etc., are some of the eminent market players.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
'
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. PREVAILING AWARENESS ABOUT POST-MENOPAUSAL ISSUES AMONG WOMEN
3.1.2. INCIDENCE OF HORMONAL DISORDERS
3.1.3. PRODUCT LAUNCHES BY MAJOR PLAYERS
3.2. KEY RESTRAINTS
3.2.1. ADVERSE REACTIONS ASSOCIATED WITH HORMONE REPLACEMENT THERAPY
3.2.2. HIGH COST OF TREATMENT
4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON HORMONE REPLACEMENT THERAPY MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRY
4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
5. MARKET BY THERAPY TYPE
5.1. ESTROGEN HORMONE REPLACEMENT THERAPY
5.2. THYROID HORMONE REPLACEMENT THERAPY
5.3. TESTOSTERONE HORMONE REPLACEMENT THERAPY
5.4. HUMAN GROWTH HORMONE REPLACEMENT THERAPY
5.5. PROGESTOGEN HORMONE REPLACEMENT THERAPY
6. MARKET BY INDICATION
6.1. MENOPAUSE
6.2. MALE HYPOGONADISM
6.3. GROWTH HORMONE DEFICIENCY
6.4. HYPOTHYROIDISM
6.5. OTHER INDICATIONS
7. MARKET BY ROUTE OF ADMINISTRATION
7.1. ORAL
7.2. PARENTERAL
7.3. TRANSDERMAL
7.4. OTHER ROUTE OF ADMINISTRATIONS
8. GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1. MARKET SIZE & ESTIMATES
8.1.2. KEY GROWTH ENABLERS
8.1.3. KEY CHALLENGES
8.1.4. KEY PLAYERS
8.1.5. COUNTRY ANALYSIS
8.1.5.1. UNITED STATES
8.1.5.2. CANADA
8.2. EUROPE
8.2.1. MARKET SIZE & ESTIMATES
8.2.2. KEY GROWTH ENABLERS
8.2.3. KEY CHALLENGES
8.2.4. KEY PLAYERS
8.2.5. COUNTRY ANALYSIS
8.2.5.1. GERMANY
8.2.5.2. FRANCE
8.2.5.3. UNITED KINGDOM
8.2.5.4. ITALY
8.2.5.5. RUSSIA
8.2.5.6. BELGIUM
8.2.5.7. POLAND
8.2.5.8. REST OF EUROPE
8.3. ASIA-PACIFIC
8.3.1. MARKET SIZE & ESTIMATES
8.3.2. KEY GROWTH ENABLERS
8.3.3. KEY CHALLENGES
8.3.4. KEY PLAYERS
8.3.5. COUNTRY ANALYSIS
8.3.5.1. CHINA
8.3.5.2. JAPAN
8.3.5.3. INDIA
8.3.5.4. AUSTRALIA & NEW ZEALAND
8.3.5.5. SOUTH KOREA
8.3.5.6. INDONESIA
8.3.5.7. THAILAND
8.3.5.8. VIETNAM
8.3.5.9. REST OF ASIA-PACIFIC
8.4. REST OF WORLD
8.4.1. MARKET SIZE & ESTIMATES
8.4.2. KEY GROWTH ENABLERS
8.4.3. KEY CHALLENGE
8.4.4. KEY PLAYERS
8.4.5. REGIONAL ANALYSIS
8.4.5.1. LATIN AMERICA
8.4.5.2. MIDDLE EAST & AFRICA
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. MERGERS & ACQUISITIONS
9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
9.1.3. PARTNERSHIPS & AGREEMENTS
9.1.4. BUSINESS EXPANSIONS, ANNOUNCEMENTS & DIVESTITURES
9.2. COMPANY PROFILES
9.2.1. ABBOTT LABORATORIES
9.2.2. AMGEN
9.2.3. ANI PHARMACEUTICALS
9.2.4. BAYER AG
9.2.5. ELI LILLY & COMPANY
9.2.6. GENENTECH INC
9.2.7. IPSEN
9.2.8. MERCK KGAA
9.2.9. NOVARTIS AG
9.2.10. NOVEN PHARMACEUTICALS INC
9.2.11. NOVO NORDISK A/S
9.2.12. PFIZER INC
9.2.13. VIATRIS INC (MYLAN NV)
1. ABBOTT LABORATORIES
2. AMGEN
3. ANI PHARMACEUTICALS
4. BAYER AG
5. ELI LILLY & COMPANY
6. GENENTECH INC
7. IPSEN
8. MERCK KGAA
9. NOVARTIS AG
10. NOVEN PHARMACEUTICALS INC
11. NOVO NORDISK A/S
12. PFIZER INC
13. VIATRIS INC (MYLAN NV)
